News

Our News

06.07.2021
BioVersys presents latest data on clinical pipeline at ECCMID 2021
05.07.2021
BIOVERSYS APPOINTS MEDICAL DIRECTOR AND HEAD OF CMC
01.06.2021
BIOVERSYS RECEIVES A SECOND CARB-X AWARD OF UP TO US$ 15.34 MILLION FOR BV300
18.05.2021
Martin Bott appointed CFO of Bioversys
14.04.2021
BioVersys receives €20 million in EU financing to support development of new antibiotics
25.02.2021
BioVersys, TASK and GSK receive 2.7 million euro from EDCTP for Phase 2a clinical trial
12.01.2021
BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BVL-GSK098
18.11.2020
BioVersys announces first subjects dosed in phase 1 clinical trial of BV100
01.09.2020
BioVersys Announces CHF 19 Million Financing to Advance Novel AMR Candidates into Clinical Development
14.07.2020
BioVersys and Partners from Lille Sign Long-term Collaboration Agreement Creating a Unique Cross-Border AMR Cluster in Antimicrobial Research Excellence
23.06.2020
BioVersys Receives QIDP Designation from the U.S. FDA for the Development of a fixed combination of BVL-GSK098 and ETH
05.05.2020
GARDP signs MOU with Swiss biotech BioVersys AG
10.12.2019
BioVersys Receives CARB-X Award of up to US$ 8.92 Million
20.06.2019
BioVersys announces a EUR 6.92 Million funding of its TRIC-TB project by the IMI2 JU and extends its successful collaboration with long term partners
27.05.2019
BioVersys Receives QIDP Designation from the U.S. FDA for the Development of BV100
05.12.2018
Dr. Glenn E. Dale Appointed CDO of BioVersys
15.11.2018
Biosystems Technology, BioVersys and Voxcan announce funding by Eurostras
15.11.2018
Eurostars Funds IMPACT2 To Establish A Break-Through Translational AMR Platform
05.07.2018
BioVersys and Institut Pasteur de Lille Working Together
20.11.2017
BioVersys AG successfully closes Series A2 financing round